Posted by Michael Wonder on 05 Feb 2016
FDA approves Merck’s single-dose Emend (fosaprepitant dimeglumine) for Injection, in combination with other anti-emetic agents, for the prevention of delayed nausea and vomiting in adults receiving moderately emetogenic chemotherapy
4 February 2016 - Emend is the first and only intravenous NK1 receptor antagonist approved in the U.S. for use in moderately emetogenic chemotherapy.
For more details, go to: http://www.mercknewsroom.com/news-release/corporate-news/fda-approves-mercks-single-dose-emend-fosaprepitant-dimeglumine-injectio
